FDA ap­proves Avadel's nar­colep­sy drug af­ter courts forced Jazz patent delist­ing

Avadel Phar­ma­ceu­ti­cals notched an FDA ap­proval for nar­colep­sy drug Lum­ryz on Mon­day fol­low­ing a mul­ti-year court bat­tle with Jazz Phar­ma­ceu­ti­cals.

Jazz was forced to delist …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER